Table 4.
Improvement rates after the final dose, stratified by background factors
| Stratification factor | Number of patients (improvement rate [%]) | |||||
|---|---|---|---|---|---|---|
| PP group | LM group | MH group | ||||
| Improved | Total | Improved | Total | Improved | Total | |
| Total | 0 | 48 (0.0) | 29 | 48 (60.4) | 21 | 50 (42.0) |
| Age (years) | ||||||
| 21–64 | 0 | 18 (0.0) | 16 | 23 (69.6) | 10 | 25 (40.0) |
| 65–86 | 0 | 30 (0.0) | 13 | 25 (52.0) | 11 | 25 (44.0) |
| Type of supraventricular tachyarrhythmias | ||||||
| Sinus tachycardia | 0 | 27 (0.0) | 19 | 32 (59.4) | 17 | 34 (50.0) |
| Others | 0 | 21 (0.0) | 10 | 16 (62.5) | 4 | 16 (25.0) |
| Site of surgery | ||||||
| Cardiac vascular surgery | 0 | 30 (0.0) | 21 | 33 (63.6) | 15 | 32 (46.9) |
| Resection of an esophageal cancer | 0 | 11 (0.0) | 6 | 10 (60.0) | 5 | 15 (33.3) |
| Thoracotomy | 0 | 3 (0.0) | 1 | 3 (33.3) | 0 | 2 (0.0) |
| Amount of dopamine/dobutamine used (μg/kg/min) | ||||||
| Not used | 0 | 6 (0.0) | 2 | 6 (33.3) | 3 | 10 (30.0) |
| 0.50–5.00 | 0 | 21 (0.0) | 15 | 24 (62.5) | 8 | 22 (36.4) |
| 5.01–10.00 | 0 | 17 (0.0) | 9 | 14 (64.3) | 7 | 13 (53.8) |
| 10.01–20.00 | 0 | 4 (0.0) | 3 | 4 (75.0) | 3 | 5 (60.0) |
| Baseline heart rate (bpm) | ||||||
| 120–129 | 0 | 19 (0.0) | 19 | 25 (76.0) | 15 | 25 (60.0) |
| 130–139 | 0 | 10 (0.0) | 7 | 13 (53.8) | 3 | 14 (21.4) |
| 140–189 | 0 | 19 (0.0) | 3 | 10 (30.0) | 3 | 11 (27.3) |
| Baseline systolic blood pressure (mmHg) | ||||||
| 92–139 | 0 | 31 (0.0) | 19 | 34 (55.9) | 14 | 35 (40.0) |
| 140–219 | 0 | 17 (0.0) | 10 | 14 (71.4) | 7 | 15 (46.7) |
| Baseline RPP (bpm · mmHg) | ||||||
| 11,280–16,999 | 0 | 21 (0.0) | 15 | 26 (57.7) | 12 | 31 (38.7) |
| 17,000–35,916 | 0 | 27 (0.0) | 14 | 22 (63.6) | 9 | 19 (47.4) |
Refer to Table 1 for treatment group definitions
bpm beats per minute